Evidence map›Paper›PMID 36560780›Full record

ArticleViruses2022

Multiple Mutations Associated with Emergent Variants Can Be Detected as Low-Frequency Mutations in Early SARS-CoV-2 Pandemic Clinical Samples.

Jeffrey Kimbrel, Joseph Moon, Aram Avila-Herrera, Jose Manuel Martí, James Thissen, Nisha Mulakken, Sarah H Sandholtz, Tyshawn Ferrell, Chris Daum, Sara Hall and 7 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. SARS-CoV-2 mutant spectrum complexity is an epidemiologically evolvable trait.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Jeffrey KimbrelLawrence Livermore National Laboratory, Livermore, CA 94550, USA.ORCID 0000-0001-7213-9392
Joseph MoonLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Aram Avila-HerreraLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Jose Manuel MartíLawrence Livermore National Laboratory, Livermore, CA 94550, USA.ORCID 0000-0002-1902-9749
James ThissenLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Nisha MulakkenLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Sarah H SandholtzLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Tyshawn FerrellLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Chris DaumLawrence Berkeley National Laboratory, US Department of Energy Joint Genome Institute, Berkeley, CA 94720, USA.ORCID 0000-0003-3895-5892
Sara HallLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Brent SegelkeLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Kathryn T ArrildtLawrence Livermore National Laboratory, Livermore, CA 94550, USA.ORCID 0000-0001-6329-6214
Sharon MessengerViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA 94804, USA.ORCID 0000-0001-6861-7267
Debra A WadfordViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA 94804, USA.ORCID 0000-0002-8630-427X
Crystal JaingLawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Jonathan E AllenLawrence Livermore National Laboratory, Livermore, CA 94550, USA.ORCID 0000-0002-4359-8263
Monica K BoruckiLawrence Livermore National Laboratory, Livermore, CA 94550, USA.ORCID 0000-0003-2924-2313
Lawrence Livermore National Laboratory · USCalifornia Department of Public Health · USLawrence Berkeley National Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic analysis of intra-host viral populations provides unique insight into pre-emergent mutations that may contribute to the genotype of future variants. Clinical samples positive for SARS-CoV-2 collected in California during the first months of the pandemic were sequenced to define the dynamics of mutation emergence as the virus became established in the state. Deep sequencing of 90 nasopharyngeal samples showed that many mutations associated with the establishment of SARS-CoV-2 globally were present at varying frequencies in a majority of the samples, even those collected as the virus was first detected in the US. A subset of mutations that emerged months later in consensus sequences were detected as subconsensus members of intra-host populations. Spike mutations P681H, H655Y, and V1104L were detected prior to emergence in variant genotypes, mutations were detected at multiple positions within the furin cleavage site, and pre-emergent mutations were identified in the nucleocapsid and the envelope genes. Because many of the samples had a very high depth of coverage, a bioinformatics pipeline, "Mappgene", was established that uses both iVar and LoFreq variant calling to enable identification of very low-frequency variants. This enabled detection of a spike protein deletion present in many samples at low frequency and associated with a variant of concern.

Indexed as

COVID-19Computational BiologyHumansMutationPandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2emergenceevolutioniSNVLoFreqmutationquasispeciessequencesevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)variant

Identifiers

PMID36560780
PMCPMC9788161
OpenAlexW4311357540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.